Worldwide drug integrated polymer fibers market is anticipated to cross US $88 million by the year 2025, according to the latest research available at Market Study Report, report provides extensively data on market share, growth, trends and forecasts for the period 2018-2025.
 

According to the report, growing R&D activities leading to innovations in biomaterials is major factor fueling the growth of drug integrated polymer fibers market. Rising population and increasing investment by government and private companies in healthcare industry along with advancements in medical textile engineering and growing adoption of implants & organ transplant practices will further boost the product demand.
 

Pharmaceutical fibers, which is another name for drug integrated polymer fibers, are produced from polylactic acid and its different derivatives and are biocompatible as well as biodegradable. The product finds applications in orthopedics, vascular grafts, drug delivery, and wound healing, among others. For its use in medical textile industry, drug integrated polymer fibers can be obtained in various forms such as woven, braided, and knitted. As the geriatric population is increasing around the globe, more and more R&D activities are being carried for material innovations to be used in wound healing and orthopedics, thereby aiding the market growth.
 

Though the innovations in pharmaceutical products and biologics along with expansion of tissue engineering & regenerative medicine are propelling the drug integrated polymer fibers market, but the prevailing use of traditional surgical procedures and high cost of the product is expected to hamper market growth over the forecast period.
 

The study cites that the drug integrated polymer fibers are currently available in the market in custom shapes & sizes depending upon its application in the biomedical sector. As these fibers can be produced using different methods, the selection of process to be used depends on the targeted use of the product. Commercially, it is manufactured through melt extrusion process. The high temperature and high shear stress of the process are, however, undesirable for pharmaceuticals and biologics, and hence wet extrusion process involving less temperature and less shear stress is being adopted.
 

Various fibers having biocompatibility and biodegradability include PCL, PGA, PLLA, and PLA. These products are manufactured using cost-effective process involving less complex machinery. The desirable mechanical and kinetics properties necessary for biomedical application can be attained by managing the shear stress, curing time, and curing temperature, cites the report.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1689416/
 

The biomedical textile applications exploit the flexibility and fibrous nature of drug integrated polymer fibers where it is used for soft tissue engineering and soft tissue replacements of cardiac muscle, blood, retina, nerve, and cartilage.
 

Considering the regional landscape, North America is dominating the global drug integrated polymer fibers market and Europe is a close competitor. These regions encompass a developed healthcare and medical industry. The increasing population and surging investment in healthcare infrastructure in the developing nations such as India and China is presumed to drive market growth in the upcoming years.
 

At present. the two key players of drug integrated polymer fibers markets are TissueGen Inc. and Micro Engineering Solutions. However, it is estimated that new players will foray into the market owing to the beneficial properties and varied applications of the product.